Schmitz G, Stumpe K O, Herrmann W, Weidinger G
Institut für Klinische Chemie und Laboratoriumsmedizin, Universität Regensburg, Germany.
Blood Press. 1996 Nov;5(6):354-9. doi: 10.3109/08037059609078074.
The effects of bunazosin and atenolol on serum lipids and lipoproteins after 6 months of treatment were compared in this multicentric, double-blind, randomised trial. A total of 174 patients with mild to moderate essential hypertension from 15 hospitals in Germany and Poland was included in the study. Eighty-seven were treated with the alpha-receptor blocker bunazosin and the same number with the beta-blocker atenolol. Systolic and diastolic blood pressure decreased significantly in both groups, whereas only atenolol decreased pulse rate. In the bunazosin group HDL-cholesterol was significantly increased after 6 months of treatment, whereas all other analysed parameters remained unchanged. In the atenolol group total cholesterol, LDL-cholesterol, total triglycerides, apolipoprotein E, VLDL-cholesterol and VLDL-triglycerides were significantly increased after 6 months of therapy. There was a significant difference between bunazosin and atenolol for total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, triglycerides, VLDL-triglycerides and apolipoprotein B levels. As a consequence, there was a significant difference in the atherogenic index of both groups. We conclude that bunazosin is favorable in the treatment of high blood pressure, because the coronary risk is not negatively influenced as shown for atenolol.
在这项多中心、双盲、随机试验中，比较了布那唑嗪和阿替洛尔治疗6个月后对血脂和脂蛋白的影响。来自德国和波兰15家医院的总共174例轻至中度原发性高血压患者纳入了该研究。87例患者接受α受体阻滞剂布那唑嗪治疗，相同数量的患者接受β受体阻滞剂阿替洛尔治疗。两组的收缩压和舒张压均显著降低，而只有阿替洛尔降低了脉率。在布那唑嗪组，治疗6个月后高密度脂蛋白胆固醇显著升高，而所有其他分析参数均保持不变。在阿替洛尔组，治疗6个月后总胆固醇、低密度脂蛋白胆固醇、总甘油三酯、载脂蛋白E、极低密度脂蛋白胆固醇和极低密度脂蛋白甘油三酯均显著升高。布那唑嗪和阿替洛尔在总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、甘油三酯、极低密度脂蛋白甘油三酯和载脂蛋白B水平方面存在显著差异。因此，两组的动脉粥样硬化指数存在显著差异。我们得出结论，布那唑嗪在高血压治疗中是有利的，因为其不像阿替洛尔那样对冠状动脉风险有负面影响。
